HIGHLIGHTS
- who: Jerome Raffenne et al. from the Institut national la santé et la recherche médicale (INSERM), Inflammation research center, Descartes University, Georges Pompidou European Hospital, France have published the research: hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status, in the Journal: (JOURNAL)
- what: The authors report the experience with the 10D7G2 and SP120 antibodies on the largest multicenter series of resected PDAC (n=471) together with the testing of three additional hENT1 commercial antibodies and mRNA levels. This study provides the largest assessment of both antibodies in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.